Dendreon (NASDAQ: DNDN) is a constant target for short-sellers, with shares down by a third for 2012 and the two-year graph looking even worse. But with a very important clinical trial on the way for Dendreon's Provenge in sequence with Johnson & Johnson's (NYSE:JNJ) drug Zytiga in a pre-chemo cancer indication, is the short-selling over? Motley Fool health care analyst David Williamson tells us why the shorts might be wrong on this one and why Dendreon might be due for a turnaround.
Dave Williamson and Brenton Flynn
Dec 11, 2012 at 6:25PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 10/20/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return